KURA News and Press, Kura Oncology Inc. From 07/24/19

SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to...

Outlook Therapeutics (NASDAQ: OTLK ) initiated with Buy rating and $8 (310% upside) at H.C. Wainwright. Shares up  11%  premarket. More news on: Outlook Therapeutics, Inc., Blueprint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the mov...

The USPTO and the European Patent Office has granted new patents to Kura Oncology (NASDAQ: KURA ), further protecting the Company's tipifarnib, a potent and selective farnesyl transferase inhibitor, currently being studied in multiple solid tumor and hematologic indications. More news on...

SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued and the Eur...

SAN DIEGO, June 21, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock, i...

"Gravity is a habit that is hard to shake off .” ― Terry Pratchett, Small Gods Today, we update the investment thesis on Kura Oncology ( KURA ) after it recently provided some new trial results and received some new analyst commentary. Company Overview: Kura Oncology...

Sesen Bio (NASDAQ: SESN )  -32%  on pricing equity offering. More news on: Sesen Bio, Inc., Tonix Pharmaceuticals Holding Corp., Calithera Biosciences, Inc., Stocks on the move, Read more ...

Kura Oncology (NASDAQ: KURA ) has priced its public offering of 5.9M common shares at $17/share, for gross proceeds of $100.3M. More news on: Kura Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...

SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 5,900,000 shares of its common stock ...

SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other cond...